Literature DB >> 16699308

Restriction of dietary Iodine does not ameliorate the early effect of anti-thyroid drug therapy for Graves' disease in an area of excessive iodine intake.

T Hiraiwa1, M Ito, A Imagawa, J Takamatsu, K Kuma, A Miyauchi, T Hanafusa.   

Abstract

The close relationship between iodine intake and the effects of anti-thyroid drugs (ATD) for Graves' disease (GD) has been well established. However, it remains unknown whether restriction of dietary iodine improves the effect of ATD. This study aimed to clarify this issue in Japanese patients with GD who routinely ingest large amounts of dietary iodine. We performed a prospective clinical study in 81 patients with newly diagnosed GD who were divided into an iodine restricted group and a control group. Urinary iodine, thyroid hormones and TSH receptor antibody were measured during the first 8 weeks of ATD therapy. Urinary iodine concentrations in the iodine restricted group were significantly lower than in the control group (p=0.043). However, there were no significant differences in the decrease of thyroid hormones and TSH receptor antibody between the two groups. Restriction of dietary iodine does not ameliorate the effect of ATD therapy for GD in an area of excessive iodine intake.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16699308     DOI: 10.1007/BF03344113

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  14 in total

1.  Urinary iodine and thyroid antibodies in Okinawa, Yamagata, Hyogo, and Nagano, Japan: the differences in iodine intake do not affect thyroid antibody positivity.

Authors:  K Nagata; N Takasu; H Akamine; C Ohshiro; I Komiya; K Murakami; A Suzawa; T Nomura
Journal:  Endocr J       Date:  1998-12       Impact factor: 2.349

2.  Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States.

Authors:  L Wartofsky; D Glinoer; B Solomon; S Nagataki; R Lagasse; Y Nagayama; M Izumi
Journal:  Thyroid       Date:  1991       Impact factor: 6.568

3.  Changes in thyroid volume in response to radioactive iodine for Graves' hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome.

Authors:  Y Murakami; J Takamatsu; S Sakane; K Kuma; N Ohsawa
Journal:  J Clin Endocrinol Metab       Date:  1996-09       Impact factor: 5.958

4.  Adherence to protein restriction in patients with type 2 diabetes mellitus: a randomized trial.

Authors:  L T Pijls; H de Vries; J T van Eijk; A J Donker
Journal:  Eur J Clin Nutr       Date:  2000-04       Impact factor: 4.016

5.  Responses of black and white males to the special intervention program of the Multiple Risk Factor Intervention Trial.

Authors:  J E Connett; J Stamler
Journal:  Am Heart J       Date:  1984-09       Impact factor: 4.749

6.  Urinary iodine levels and thyroid diseases in children; comparison between Nagasaki and Chernobyl.

Authors:  K Ishigaki; H Namba; N Takamura; H Saiwai; V Parshin; T Ohashi; T Kanematsu; S Yamashita
Journal:  Endocr J       Date:  2001-10       Impact factor: 2.349

7.  Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.

Authors:  E Roti; E Gardini; R Minelli; L Bianconi; M Salvi; G Gavaruzzi; L E Braverman
Journal:  J Clin Endocrinol Metab       Date:  1993-04       Impact factor: 5.958

8.  Effect of iodine restriction on thyroid function in patients with primary hypothyroidism.

Authors:  Kanji Kasagi; Masahiro Iwata; Takashi Misaki; Junji Konishi
Journal:  Thyroid       Date:  2003-06       Impact factor: 6.568

9.  The mechanism of action of the thioureylene antithyroid drugs.

Authors:  A Taurog
Journal:  Endocrinology       Date:  1976-04       Impact factor: 4.736

10.  Clinical evaluation of the iodide/creatinine ratio of casual urine samples as an index of daily iodide excretion in a population study.

Authors:  N Konno; K Yuri; K Miura; M Kumagai; S Murakami
Journal:  Endocr J       Date:  1993-02       Impact factor: 2.349

View more
  5 in total

1.  When should antithyroid drug therapy to reduce the relapse rate of hyperthyroidism in Graves' disease be discontinued?

Authors:  Suyeon Park; Eyun Song; Hye-Seon Oh; Mijin Kim; Min Ji Jeon; Won Gu Kim; Tae Yong Kim; Young Kee Shong; Doo Man Kim; Won Bae Kim
Journal:  Endocrine       Date:  2019-06-24       Impact factor: 3.633

2.  Excessive iodine intake does not increase the recurrence rate of graves' disease after withdrawal of the antithyroid drug in an iodine-replete area.

Authors:  Sun Mi Park; Yoon Young Cho; Ji Young Joung; Seo Young Sohn; Sun Wook Kim; Jae Hoon Chung
Journal:  Eur Thyroid J       Date:  2015-03-04

3.  Prevalence and Treatment Outcomes of Marine-Lenhart Syndrome in Japan.

Authors:  Hirosuke Danno; Eijun Nishihara; Kazuyoshi Kousaka; Tomohiko Nakamura; Toshihiko Kasahara; Takumi Kudo; Mitsuru Ito; Shuji Fukata; Mitsushige Nishikawa; Akira Miyauchi
Journal:  Eur Thyroid J       Date:  2020-09-30

4.  Guidelines for the treatment of childhood-onset Graves' disease in Japan, 2016.

Authors:  Kanshi Minamitani; Hirokazu Sato; Hidemi Ohye; Shohei Harada; Osamu Arisaka
Journal:  Clin Pediatr Endocrinol       Date:  2017-04-22

5.  Antithyroid Drug Treatment in Graves' Disease.

Authors:  Jae Hoon Chung
Journal:  Endocrinol Metab (Seoul)       Date:  2021-06-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.